Recent trends in morbidity and mortality following percutaneous nephrostomy insertion J.D. Gill, D. Burton, D. Scullion, R. Mawhinney, P. Singh, A-M. Davies and R. Kimber Harrogate District Hospital, Harrogate, UK

Methods All patients undergoing All patients undergoing PCN over 6 year period PCN over 6 year period at Harrogate at Harrogate 189 PCNs on 142 patients 189 PCNs on 142 patients 86 (60.6%) - benign 86 (60.6%) - benign 56 (39.4%) - malignant 56 (39.4%) - malignant 62 (32.8%) antegrade stents 62 (32.8%) antegrade stents 6 failed antegrade stents 6 failed antegrade stents Malignant – 34% LT neph. Malignant – 34% LT neph. DiagnosisNo. Patients Prior to PCNL31 Ureteric Stone24 Bladder Cancer21 Prostate Cancer15 PUJ Obstruction7 Colorectal Cancer6 Unknown6 Ureteric/VUJ Stricture6 Gynae cancer5 Breast Cancer3 RPF3 Iatrogenic Injury3 Other15

Results Median Survival (weeks) Type of Malignancy (No. patients) Prior cancer treatment No prior cancer treatment Combined (range) Bladder (21) (2-157) Prostate (15) (2-139) Colorectal (6) 20NA 20 (0-111) Gynaecological (5)82 NA 82 (5-103) Breast (3) 68NA 68 (11-70) Ureteric (2) NA55 55 (31-80) Lymphoma (2) NA (43-381) Oesophageal (1) 4NA 4 Unknown (1) NA1 1

Conclusions PCN common procedure PCN common procedure No immediate complications No immediate complications Lower survival in urological malignancies and in those with prior cancer treatment Lower survival in urological malignancies and in those with prior cancer treatment Appropriate counselling important Appropriate counselling important